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Summary
 
The mechanisms that regulate the strength and duration of CD8
 
1
 
 cytotoxic T cell activity
determine the effectiveness of an antitumor immune response. To better understand the anti-
tumor effects of anti-cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) antibody treat-
ment, we analyzed the effect of CTLA-4 signaling on CD8
 
1
 
 T cells in vitro and in vivo. In
vitro, cross-linking of CTLA-4 on purified CD8
 
1
 
 T cells caused decreased proliferative responses
to anti-CD3 stimulation and rapid loss of activation marker expression. In vivo, blockade of
CTLA-4 by neutralizing anti–CTLA-4 mAb greatly enhanced the accumulation, activation,
and cytotoxic activity of CD8
 
1
 
 T cells induced by immunization with Ag on dendritic cells
(DC). This enhanced response did not require the expression of MHC class II molecules on
DC or the presence of CD4
 
1
 
 T cells. These results demonstrate that CTLA-4 blockade is able to
directly enhance the proliferation and activation of specific CD8
 
1
 
 T cells, indicating its potential
for tumor immunotherapy even in situations in which CD4
 
1
 
 T cell help is limited or absent.
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aive T cells require two distinct signals to proliferate
and differentiate into armed effector cells. Signal 1 is
Ag-specific and generated by interaction of the TCR with
antigenic peptide associated with MHC molecules on APC.
Signal 2 is referred to as costimulatory because, while es-
sential, it does not by itself induce any functional response
in T cells. The most well characterized costimulatory signal
is generated through the interaction of the T cell molecule
CD28 with its ligands B7-1 and B7-2 on APC (1).
Negative costimulation also plays an important role in the
regulation of T cell activation and peripheral T cell homeo-
stasis. Interaction of B7 with cytotoxic T lymphocyte–asso-
ciated antigen 4 (CTLA-4), expressed on activated T cells,
mediates a negative signal that inhibits T cell proliferation
(2). The importance of CTLA-4 in T cell proliferation is
highlighted by the phenotype observed in CTLA-4–defi-
cient mice, which is characterized by CD4
 
1
 
 T cell–driven
polyclonal expansion of peripheral T cells, multiorgan lym-
phocytic infiltration, and death at three to four weeks of
age (3–5).
In vitro, signals mediated by CTLA-4 decrease IL-2 pro-
duction and IL-2 receptor expression and inhibit cell cycle
progression (for review, see reference 2). In vivo, CTLA-4
signaling can be blocked by administration of anti–CTLA-4
mAb, resulting in enhanced T cell immune responses to Ag
(6) or superantigen (7). Similarly, Th2-type immune responses
to nematode parasite infection (8) and Th1-type immune re-
sponses to mycobacteria can be augmented by anti–CTLA-4
treatment (Kirman, J., K. McCoy, S. Hook, M. Prout, B.
Delahunt, I. Orme, A. Frank, and G. Le Gros, manuscript
submitted for publication), and autoimmune conditions are
exacerbated (9–11). Antitumor immune responses are also
augmented by preventing CTLA-4 function (12), as dem-
onstrated by the enhanced tumor rejection in mice treated
with anti–CTLA-4 mAb.
In this study, we have sought to define a potential mech-
anism for anti–CTLA-4–induced tumor immunity. We
have reasoned that a B7-expressing cell must be involved,
presenting tumor antigen and providing ligands for CTLA-4
on T cells and thus inducing incomplete or transient activa-
tion of antitumor T cells. Current understanding suggests
that this cell is a dendritic cell (DC). Anti–CTLA-4 mAb
may enhance the activation of Ag-specific CD8
 
1
 
 T cells
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via DC by either directly preventing the engagement of
CTLA-4 on CD8
 
1
 
 T cells or enhancing CD4
 
1
 
 helper func-
tion. We find that anti–CTLA-4 treatment significantly en-
hances the expansion and cytotoxic activity of CD8
 
1
 
 T cells
activated by Ag on DC and that this enhancement can oc-
cur independently of CD4
 
1
 
 T cell help.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were obtained from The Jackson Labo-
ratory. Strain 318 TCR-transgenic mice (13) were provided by
Prof. H. Pircher (University of Freiburg, Freiburg, Germany) and
B6Aa
 
0
 
/Aa
 
0
 
 (MHC class II
 
2
 
/
 
2
 
) mice (14) by Dr. H. Blüthmann
(Hoffmann-La Roche, Basel, Switzerland). All mice were bred
and maintained at the Biomedical Research Unit of the Welling-
ton School of Medicine.
 
In Vitro Culture Media and Reagents.
 
Cultures were in IMDM
and additives were as described (8). The lymphocytic choriomen-
ingitis virus glycoprotein peptide KAVYNFATM (LCMV
 
33–41
 
)
was obtained from Chiron Mimotopes. Supernatant from the cell
line IL2L6 was used as a source of human rIL-2.
 
Antibodies and FACS
 
®
 
 Staining.
 
Anti–CTLA-4 clone UC10-
4F10-11 (provided by Dr. J. Bluestone, University of Chicago,
Chicago, IL), anti-CD3 (145-2C11), anti-CD28 (37.51), anti-
CD8 (2.43), anti-CD4 (GK1.5), anti-CD11c (N418), anti-Fc
 
g
 
RII
(2.4G2), anti-V
 
b
 
8.1/8.2 (KJ16.133.18), and anti-CD44 (I42/5)
were affinity purified from culture supernatants using protein
G–Sepharose (Pharmacia Biotech) and conjugated to FITC or bio-
tin. Anti-V
 
a
 
2–PE mAb and streptavidin–Cy-Chrome were ob-
tained from PharMingen. Control IgG was affinity purified from
hamster serum using protein G–Sepharose. Cells were stained in
PBS containing 2% FCS and 0.01% sodium azide as described (15).
 
In Vitro CTLA-4 Cross-linking Experiments.
 
Lymph node cell
suspensions were layered onto a Percoll gradient (Pharmacia Bio-
tech AB) and the high density cells taken from the interface of 60
and 70% Percoll layers. CD4
 
1
 
 and Ig
 
1
 
 cells were depleted by
treatment with anti-CD4 mAb followed by anti-Ig magnetic
bead adherence (Dynal A.S.). The remaining cell suspension con-
tained 95% CD8
 
1
 
 T cells, with no detectable CD4
 
1
 
 T cells and
 
,
 
2% B220
 
1
 
 cells. For cross-linking experiments, 10
 
5
 
 resting
CD8
 
1
 
-enriched cells were cultured with 10
 
5
 
 polystyrene beads
coated with anti-CD3 and either anti–CTLA-4 or control IgG in
the presence or absence of soluble anti-CD28 as described (16).
Control cultures were provided with 50 U/ml human rIL-2.
Proliferation was determined by 
 
3
 
H-TdR incorporation over the
last 8 h of a 72-h culture.
 
Culture of Bone Marrow–derived DC and Ag Loading.
 
Bone mar-
row cells from C57BL/6 mice or MHC class II
 
2
 
/
 
2
 
 mice were
cultured in 20 ng/ml IL-4 and 20 ng/ml GM-CSF for 6–8 d
as described (17). Cultures typically contained 90–100% DC as
determined by FACS
 
®
 
 staining with anti-CD11c mAb. DC were
loaded with Ag by incubation in medium containing 10 
 
m
 
M
LCMV
 
33–41
 
 for 2 h.
 
Adoptive Transfer and Immunization.
 
Lymph node cell suspen-
sions were prepared from line 318 mice, and the percentage of
T cells expressing transgenic TCR was determined by flow cytom-
etry using anti-TCR V
 
a
 
2 and anti-TCR V
 
b
 
8.1/8.2 mAb. The
equivalent of 3–5 
 
3
 
 10
 
6
 
 V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
 T cells were injected intra-
venously into C57BL/6 recipients, and on the same day, mice
were given an intraperitoneal injection of 1 mg anti–CTLA-4
mAb or control IgG. 1 d later, recipients were immunized by sub-
cutaneous injection of 10
 
5
 
 LCMV
 
33–41
 
 peptide–loaded DC or un-
 
treated DC in IMDM. For each experiment, a group of adoptive
transfer recipients was left unmanipulated to serve as a control.
For experiments in MHC class II
 
2
 
/
 
2
 
 recipients, the donor cell
preparations were depleted of CD4
 
1
 
 and Ig
 
1
 
 cells as described
above.
 
Direct Cytotoxicity Assays.
 
C57BL/6 mice received TCR-trans-
genic T cells, were treated with anti–CTLA-4 or control IgG,
and were immunized with 3 
 
3
 
 10
 
4
 
 DC as described above. 7 d
after DC immunization, splenocytes were harvested, depleted of
CD4
 
1
 
 and Ig
 
1
 
 cells, and tested for cytotoxic activity in vitro by
JAM test on 5,000 labeled EL4 cells that had been incubated in the
presence or absence of 1 
 
m
 
M LCMV
 
33–41
 
 peptide for 1 h at 37
 
8
 
C
before the assay (18). All cultures were performed in triplicate.
 
Results
 
CTLA-4 Mediates a Negative Regulatory Signal to Purified
CD8
 
1
 
 T Cells In Vitro.
 
We used anti–CTLA-4 mAb con-
jugated to polystyrene beads to examine the effect of
CTLA-4 cross-linking on the activation and proliferation
of purified resting CD8
 
1
 
 T cells in culture. Lymphocyte
preparations from line 318 TCR-transgenic mice were de-
pleted of CD4
 
1
 
 and Ig
 
1
 
 cells using Ab-coated magnetic
beads. Enriched CD8
 
1
 
 T cells were cultured with beads
coated with either anti-CD3 and anti–CTLA-4 or anti-
CD3 and control IgG in the presence of a positive costim-
ulatory signal provided by soluble anti-CD28. As shown in
Fig. 1 A, after 24 h both control Ab–treated and anti–
CTLA-4–treated cultures contained activated CD8
 
1
 
 T cells
with markedly increased expression of the activation mark-
ers CD25 and CD69 as compared to resting cells. However,
whereas expression of these activation markers was main-
tained until after 48 h in control cultures, it was rapidly lost
in the presence of anti–CTLA-4. No increase in cell death
was apparent in anti–CTLA-4–treated cultures as compared
to control cultures (data not shown). Proliferation of CD8
 
1
 
T cells in these cultures was assayed 64–72 h after activa-
tion (Fig. 1 B). In the presence of anti-CD28, control cul-
tures were highly activated and showed significant levels of
proliferation. In contrast, cross-linking of CTLA-4 with
mAb-conjugated beads completely inhibited proliferation.
The inhibitory function of anti–CTLA-4 was overridden
by addition of exogenous IL-2. Therefore, the proliferative
function of CD8
 
1
 
 T cells can be directly inhibited by
signals mediated via CTLA-4. Similar results have been re-
ported by Walunas et al. using CD8
 
1
 
 T cells from the
TCR-transgenic strain 2C (19).
 
Anti–CTLA-4 mAb Treatment In Vivo Enhances DC-induced
CD8
 
1
 
 T Cell Activation and Accumulation.
 
To determine
whether CTLA-4 signals regulate the activation of CD8
 
1
 
T cells in vivo, we examined the effect of a neutralizing anti–
CTLA-4 mAb on the accumulation of specific CD8
 
1
 
 T cells
in the lymph nodes of mice immunized with Ag-loaded
DC. An adoptive transfer model was used (15) in which
nonmanipulated C57BL/6 hosts received 5 
 
3
 
 10
 
6
 
 TCR-
transgenic T cells from strain 318 mice. These T cells are
specific for LCMV
 
33–41
 
 in association with H-2D
 
b
 
 and can
be identified by their V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD8
 
1
 
 phenotype. Anti–
CTLA-4 mAb or control IgG was administered intraperi- 
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toneally at the time of adoptive transfer, followed by DC
loaded with LCMV
 
33–41
 
 peptide on day 1. Control animals
received either DC that had not been loaded with Ag or no
DC immunization at all. Activation and accumulation of
V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD8
 
1
 
 T cells in the draining lymph nodes
were examined on day 5 after immunization, as preliminary
experiments showed that both responses were maximal on
this day (data not shown). The data in Fig. 2 are presented
as fold increase in the total number of V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD8
 
1
 
T cells in immunized mice over the number of the same
cells in animals that were not immunized. This is because
the fold increase in V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD8
 
1
 
 T cells was repro-
ducible in different experiments, whereas the absolute cell
number varied. In control IgG–treated animals, an average
2.4-fold increase in the number of V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD8
 
1
 
 T cells
was observed in response to Ag-loaded DC, whereas immu-
nization with DC without Ag failed to induce any increase.
Significantly, when animals were treated with anti–CTLA-4
mAb, the Ag-induced accumulation was greater, with an
average sixfold increase observed. This reflected both an
increase in the proportion of V
 
a
 
2
 
1
 
V
 
b
 
8
 
1
 
CD81 T cells and
an increase in the total number of lymph node cells (two-
fold). Immunization with Ag-loaded DC induced increased
CD44 expression on a significant proportion of Va21Vb81
T cells, and this proportion was greatly increased in animals
treated with anti–CTLA-4 mAb (Fig. 2). Importantly, in-
creased CD44 expression was strictly Ag dependent and
was not detected on cells not expressing the Va21Vb81 re-
ceptor. Interestingly, a twofold increase in the cellularity of
the draining lymph node, with no increase in the percentage
of Va21Vb81CD81 cells, was observed in mice treated with
anti–CTLA-4 and immunized with DC only, resulting
in an increase in the absolute number of Va21Vb81 cells.
The increased cellularity was immunization related, as it was
not observed in nondraining lymph nodes. No increased
expression of CD44 or other activation markers was ob-
served on these Va21Vb81 cells (not shown), indicating
that blockade of CTLA-4 signals was not sufficient to induce
T cell activation in the absence of Ag. Taken together, these
results suggest that inhibition of CTLA-4–mediated signal-
ing results in enhanced Ag-specific proliferation of CD81
T cells in vivo.
Figure 1. Cross-linking of surface CTLA-4 mole-
cules inhibits activation and proliferation of purified
CD81 T cells. Resting CD81 T cells were isolated from
the lymph nodes of line 318 transgenic mice and cul-
tured with sterile polystyrene beads coated with either
anti-CD3 and anti–CTLA-4 or anti-CD3 and control
hamster IgG. Cultures were provided either no costim-
ulus, soluble anti-CD28, or soluble anti-CD28 and rIL-2. (A) Expression of the activation markers
CD25 and CD69 on resting CD81 T cells and on CD81 T cells cultured in the presence (thick line) or
absence (dotted line) of anti–CTLA-4. (B) 3H-TdR uptake by CD81 T cells cultured in the same con-
ditions, measured 72 h after stimulation. Results are shown as the average of triplicate wells 6 SE.
Figure 2. Treatment with anti–CTLA-4 mAb
augments the accumulation and activation of adop-
tively transferred CD81 T cells in the lymph nodes
of mice immunized with DC. (A) Numbers of
Va21Vb81CD81 cells were determined in the
lymph nodes of experimental mice (n 5 4–8) 5 d af-
ter immunization with DC and are presented as the
average 6 SE fold increase in the total number of
Va21Vb81CD81 T cells over the corresponding
nonimmunized adoptive transfer controls. Com-
bined results from two experiments are shown.
Numbers of Va21Vb81CD81 T cells in nonim-
munized adoptive transfer controls varied between
3 3 104 and 105 over two different experiments.
Mice received treatment with anti–CTLA-4 mAb
or control IgG as indicated. (B) Representative
stainings from mice immunized with DC 1 Ag.
CD44 expression on gated Va21Vb81 cells was
determined by triple staining and FACS® analysis.1160 CTLA-4 Directly Regulates CD81 Cells
Enhanced CD81 T Cell Activation In Vivo by Anti–CTLA-4
mAb Treatment Is Not a Result of Increased CD41 T Helper
Function. It was possible that the enhanced CD81 T cell
activation induced by anti–CTLA-4 mAb treatment was
due to increased helper function of CD41 T cells. To ex-
amine this possibility, we repeated the DC immunization
experiments using MHC class II2/2 DC, which are unable
to present Ag to CD41 T cells and elicit T cell help. MHC
class II2/2 mice were also used as immunization recipients,
as in these mice, no T cell help would be available if Ag
was transferred from the injected DC to host APC.
As shown in Fig. 3, immunization with MHC class II2/2
DC loaded with LCMV33–41 peptide induced selective accu-
mulation of Va21Vb81CD81 T cells in the draining lymph
nodes of MHC class II1/1 and MHC Class II2/2 mice.
More importantly, treatment with anti–CTLA-4 mAb sig-
nificantly enhanced the accumulation of Va21Vb81CD81
T cells (Fig. 3) and their expression of CD44 (not shown),
regardless of the expression of MHC class II on host APC.
Again, as for Fig. 2, treatment with anti–CTLA-4 caused
an increase in the cellularity of the draining lymph node in
mice immunized with DC only; however, the percentage of
Va21Vb81CD81 cells was not increased compared to con-
trols nor was their expression of activation markers altered.
These results suggest that the enhanced accumulation of
Va21Vb81 T cells observed with anti–CTLA-4 treatment
in DC-immunized mice is not dependent on the provision
of CD41 T cell help. We conclude that CD81 T cells can be
directly regulated in vivo by signals mediated via CTLA-4
molecules.
Anti–CTLA-4 mAb Treatment In Vivo Enhances Ag-specific
Cytotoxicity Measured In Vitro. To determine whether in
vivo treatment with anti–CTLA-4 mAb affects the effector
function of CD81 T cells, we assayed cytotoxic activity in
mAb-treated adoptive transfer recipients that had been im-
munized with DC. Spleen cells were recovered 7 d after
immunization, depleted of CD41 T cells and Ig1 cells, and
assayed directly on LCMV33–41 peptide–coated EL4 targets.
As is seen in Fig. 4, Ag-specific cytotoxicity was barely de-
tectable when CD81 effector cells were prepared from
DC-immunized, control IgG–treated mice. Therefore, the
cytotoxic activity induced by DC immunization was below
the threshold of detection by this technique. In contrast, in
vivo treatment with anti–CTLA-4 mAb resulted in a mea-
surable increase in specific cytotoxicity, with 50% lysis ob-
served at an E/T ratio of 150:1 when MHC class II1/1 DC
were used for immunization. When MHC class II2/2 DC
were used, 35% lysis was observed. Increased cytotoxic ac-
tivity of effector CD81 T cells in the anti–CTLA-4–treated
groups was apparent even when the E/T ratios were ad-
justed for the percentage of Va21Vb81 cells (data not
shown). These results indicate that CTLA-4–mediated sig-
nals regulate the cytotoxic activity of CD81 T cells, also in
the absence of CD41 help.
Discussion
In this paper, we show that CD81 T cell responses in-
duced by Ag presented on DC are amplified when CTLA-
4–dependent signaling is inhibited in vivo. While anti–
CTLA-4 mAb treatment was known to enhance several
kinds of T cell immune responses (6–11), it had not been
previously reported that increased CD81 T cell activation
is also observed when DC are used as APC, a finding
that may have significant implications for the use of anti–
CTLA-4 in tumor immunotherapy.
We investigated whether anti–CTLA-4 enhanced the ac-
tivity of CD81 T cells directly or by increasing the availabil-
Figure 3. Treatment with anti–CTLA-4 mAb augments the accumula-
tion of CD81 T cells in the lymph nodes of immunized mice regardless of
the availability of T cell help. Groups of C57BL/6 (A) or MHC class II2/2
(B) recipient mice (n 5 4–11) received 5 3 106 Va21Vb81CD81 T cells
from line 318 transgenic donors, were treated with either anti–CTLA-4
mAb or control IgG, and were immunized with MHC class II2/2 DC as
described in the Fig. 2 legend. Combined data are shown as for Fig. 2.
The number of Va21Vb81CD81 T cells in nonimmunized adoptive
transfer controls varied between 3 3 104 and 1.5 3 105 over three differ-
ent experiments for the data in A and between 1.9 3 104 and 2.4 3 104
over two different experiments for the data in B.
Figure 4. Treatment with anti–CTLA-4 mAb during in vivo immuni-
zation with DC enhances the direct, Ag-specific cytotoxicity measured in
vitro. C57BL/6 recipient mice received 5 3 106 Va21Vb81CD81 T cells
from line 318 transgenic donors, were treated with either control IgG
or anti–CTLA-4 mAb, and were immunized with 3 3 104 LCMV33–41
peptide–loaded DC from C57BL/6 or MHC class II2/2 mice as described
for Fig. 2. 7 d after immunization, spleen cell suspensions were prepared
and depleted of CD41 T cells and Ig1 cells by magnetic adherence. Cyto-
toxic activity was measured in vitro by JAM test on EL4 targets or on EL4 1
LCMV33–41 peptide.1161 McCoy et al. Brief Definitive Report
ity of CD41 T cell help. To this purpose, we carried out
experiments in which the potential contribution of CD41
T cells to the CD81 T cell response was progressively re-
duced. We observed augmented CD81 T cell responses re-
gardless of the availability of CD41 T cells, indicating that
CD41 T cells were not critical to the observed effect. As also
reported by Walunas et al. (19), a purified cell culture sys-
tem confirmed that CD81 T cells could respond directly to
CTLA-4–mediated signals in vitro. However, although it is
clear that the effects of anti–CTLA-4 we have observed are
independent of CD41 T cell help, CD41 T cells are thought
to be necessary for the activation of DC and for the produc-
tive development of a CD81 T cell response (20). Because
we could observe good CD81 T cell responses even in the
absence of CD41 T cells, we must conclude that our DC
were sufficiently activated before injection to be able to in-
duce good CD81 T cell priming.
The findings reported in this paper are relevant to the
described enhancement of tumor immunity induced by in
vivo treatment with anti–CTLA-4 mAb (12). Treatment
with anti–CTLA-4 mAb in vivo is thought to block the
delivery of a negative signal, mediated by B7 ligands on
B7-expressing cells. Because tumor cells are generally B72,
a third cell type must be providing B7 in this system. Bone
marrow–derived APC, presumably DC, have been re-
ported to take up and present self Ag (21) as well as tumor
Ag (22) from peripheral tissues in physiological situations.
We thus hypothesized that tumor immunity induced by
anti–CTLA-4 treatment is most likely due to enhanced
T cell activation by tumor antigen presented by DC. In this
paper, we show that both CD81 T cell activation and spe-
cific cytotoxic activity induced by immunization with DC
are amplified in the presence of anti–CTLA-4 mAb, possi-
bly resulting in the tumor immunity described by Leach
et al. (12). Our results also imply that tumors in which Ag
fails to gain access to a DC, because of either poor anti-
genicity or limited DC presence in the tumor, may fail to
respond to anti–CTLA-4 treatment. Conversely, manip-
ulations which increase local inflammation and therefore
access of tumor Ag to DC (23), or tumor vaccination pro-
cedures, could become more effective if used in combina-
tion with anti–CTLA-4 treatment (24).
As in the case of CTLA-4–deficient mice (25), we could
observe no spontaneous T cell activation in the absence of
Ag when CTLA-4 signaling was blocked. Surprisingly,
however, we observed that lymph node cellularity was in-
creased by anti–CTLA-4 treatment even after immuni-
zation with DC only. This increase was restricted to the
draining lymph nodes, indicating that it was immunization
related. DC have been reported to induce Ca21 responses
in T cells in the absence of Ag (26). This low level of
stimulation may be amplified by the removal of CTLA-4
signals.
In conclusion, blockade of CTLA-4 directly enhances the
ability of CD81 T cells to respond to Ag presented on DC,
amplifying their expansion and accumulation in lymphoid
organs and their cytotoxic activity. This finding may help
explain the antitumor effect of anti–CTLA-4 mAb treat-
ment, and, if extended to CD41 T cells, the autoimmune
phenotype observed in CTLA-4–deficient mice.
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